AWM
XENE icon

Avior Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

Avior Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,569
Closed -$101K – 2368
2024
Q4 		$101K Buy
+2,569
New +$106K ﹤0.01% 893
2024
Q2 		– Sell
-302
Closed -$13K – 3752
2024
Q1 		$13K Buy
+302
New +$13.9K ﹤0.01% 1772

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Avior Wealth Management's XENE Position: Q1 2025 in Review

Avior Wealth Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 2,569 shares — an estimated $101K sold.

Avior Wealth Management first reported a position in XENE in Q1 2024 and held it in 2 quarters. The position peaked at $101K in Q4 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Avior Wealth Management reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 2,569 Xenon Pharmaceuticals shares in Q1 2025, an estimated $101K.
  • Avior Wealth Management first reported a position in Xenon Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Avior Wealth Management's Xenon Pharmaceuticals position peaked at $101K in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.